Since their introduction in 2010, non-vitamin K oral anticoagulants (NOACs) changed the landscape of stroke prevention in patients with atrial fibrillation (AF). Because of their favorable benefit-harm profile, the fixed dose administration, the no need for laboratory monitoring and dose adjustment, NOAC prescription increased rapidly and overcome the use of vitamin K antagonists (VKAs)
Patients with Atrial Fibrillation receiving NOACs: The boundary between appropriate and inappropriate dose
Paciaroni M.Ultimo
2021
Abstract
Since their introduction in 2010, non-vitamin K oral anticoagulants (NOACs) changed the landscape of stroke prevention in patients with atrial fibrillation (AF). Because of their favorable benefit-harm profile, the fixed dose administration, the no need for laboratory monitoring and dose adjustment, NOAC prescription increased rapidly and overcome the use of vitamin K antagonists (VKAs)File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
